Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma.
Few data are available on the efficacy of the combination of lenalidomide plus dexamethasone (Len/Dex) in very elderly patients above 75 years of age with relapsed multiple myeloma (MM). We report here a single-center series of 45 consecutive patients aged 75 years or older with relapsed MM treated with this combination. The overall response rate was 62% and the median progression-free survival was 14 months, which compares favorably to that described in the two pivotal prospective studies that formed the basis for the approval of Len/Dex in the relapse setting. Our study confirms that Len/Dex is an effective combination in very elderly patients with relapsed MM.
Hematology Department, University Hospital of Nantes, France.
Cyrille
C
Touzeau
Nicolas
N
Blin
Aline
A
Clavert
Virginie
V
Roland
Marion
M
Loirat
Benoit
B
Tessoulin
Steven
S
Le Gouill
Lucie
L
Planche
Martine
M
Pennetier
Beatrice
B
Mahe
Mohamad
M
Mohty
Florent
F
Malard
Pierre
P
Peterlin
Viviane
V
Dubruille
Philippe
P
Moreau
D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage; D018450:Disease Progression; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence; D012189:Retrospective Studies; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome
D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide